These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10803495)

  • 1. Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection.
    Isogai E; Isogai H; Hayashi S; Kubota T; Kimura K; Fujii N; Ohtani T; Sato K
    Microbiol Immunol; 2000; 44(2):89-95. PubMed ID: 10803495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of anti-TNF-alpha antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection.
    Isogai E; Isogai H; Hirose K; Kubota T; Kimura K; Fujii N; Hayashi S; Takeshi K; Oguma K
    Comp Immunol Microbiol Infect Dis; 2001 Oct; 24(4):217-31. PubMed ID: 11561957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic effects of antibiotics against enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157) infection: in vivo analysis using germfree mice].
    Sawamura S; Tanaka K; Koga Y
    Kansenshogaku Zasshi; 1999 Oct; 73(10):1054-63. PubMed ID: 10565122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo synergy between green tea extract and levofloxacin against enterohemorrhagic Escherichia coli O157 infection.
    Isogai E; Isogai H; Hirose K; Hayashi S; Oguma K
    Curr Microbiol; 2001 Apr; 42(4):248-51. PubMed ID: 11178724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model.
    Yoshimura K; Fujii J; Taniguchi H; Yoshida S
    FEMS Immunol Med Microbiol; 1999 Nov; 26(2):101-8. PubMed ID: 10536295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection.
    Hiramatsu K; Murakami J; Kishi K; Hirata N; Yamasaki T; Kadota J; Shibata T; Nasu M
    Int J Antimicrob Agents; 2003 May; 21(5):471-7. PubMed ID: 12727082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does levofloxacin induce hemolytic uremic syndrome in patients infected with verotoxin-producing Escherichia coli O157 infections?
    Ohnishi K; Nakamura-Uchiyama F
    Jpn J Infect Dis; 2012; 65(5):442-3. PubMed ID: 22996222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition.
    Kurioka T; Yunou Y; Harada H; Kita E
    Eur J Clin Microbiol Infect Dis; 1999 Aug; 18(8):561-71. PubMed ID: 10517193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7.
    Yoh M; Frimpong EK; Honda T
    FEMS Immunol Med Microbiol; 1997 Sep; 19(1):57-64. PubMed ID: 9322069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.
    Zhang X; McDaniel AD; Wolf LE; Keusch GT; Waldor MK; Acheson DW
    J Infect Dis; 2000 Feb; 181(2):664-70. PubMed ID: 10669353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis--effect of various antibiotics on extracellular release of verotoxin].
    Ito T; Akino E; Hiramatsu K
    Kansenshogaku Zasshi; 1997 Feb; 71(2):130-5. PubMed ID: 9077070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents.
    Grif K; Dierich MP; Karch H; Allerberger F
    Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):761-6. PubMed ID: 9923515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection?
    Panos GZ; Betsi GI; Falagas ME
    Aliment Pharmacol Ther; 2006 Sep; 24(5):731-42. PubMed ID: 16918877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro.
    Yoh M; Honda T
    Epidemiol Infect; 1997 Aug; 119(1):101-3. PubMed ID: 9287950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro.
    Murakami J; Kishi K; Hirai K; Hiramatsu K; Yamasaki T; Nasu M
    Int J Antimicrob Agents; 2000 Jul; 15(2):103-9. PubMed ID: 10854805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Activity of fosfomycin against Escherichia coli O157:H7--morphological changes and production of Shiga toxins].
    Takata T; Tabata M; Tsuruoka T; Watabe H
    Jpn J Antibiot; 2003 Dec; 56(6):691-6. PubMed ID: 15007877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tumor necrosis factor alpha in gnotobiotic mice infected with an Escherichia coli O157:H7 strain.
    Isogai E; Isogai H; Kimura K; Hayashi S; Kubota T; Fujii N; Takeshi K
    Infect Immun; 1998 Jan; 66(1):197-202. PubMed ID: 9423858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental infection of germ-free mice with hyper-toxigenic enterohaemorrhagic Escherichia coli O157:H7, strain 6.
    Taguchi H; Takahashi M; Yamaguchi H; Osaki T; Komatsu A; Fujioka Y; Kamiya S
    J Med Microbiol; 2002 Apr; 51(4):336-343. PubMed ID: 11926740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
    Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
    Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis].
    Fukuyama M; Furuhata K; Oonaka K; Hara T; Sunakawa K
    Jpn J Antibiot; 2000 Jul; 53(7):522-31. PubMed ID: 11019386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.